Cited by 1,322PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and CancerAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.

mTOR and cancer: insights into a complex relationship

Sabatini, David M.·2006·Nature Reviews Cancer

DOI 10.1038/nrc1974

Open this paper in CoChat — free account

Abstract

mTOR (mammalian target of rapamycin) has come a long way since its humble beginnings as a kinase of unknown function. As part of the mTORC1 and mTORC2 complexes mTOR has key roles in several pathways that are involved in human cancer, stimulating interest in mTOR inhibitors and placing it on the radar of the pharmaceutical industry. Here, I discuss the rationale for the use of drugs that target mTOR, the unexpectedly complex mechanism of action of existing mTOR inhibitors and the potential benefits of developing drugs that function through different mechanisms. The purpose is not to cover all aspects of mTOR history and signalling, but rather to foster discussion by presenting some occasionally provocative ideas.

Integrity signals

Registry

Crossref · 10.1038/nrc1974

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Self-citation
Upstream and downstream of mTOR
Hay, N., & Sonenberg, N. (2004) · Genes & Development · doi:10.1101/gad.1212704 · Cited by 4,181
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling
Inoki, K., Li, Y., Zhu, T., Wu, J., & Guan, K.-L. (2002) · Nature Cell Biology · doi:10.1038/ncb839 · Cited by 3,083
mTOR Interacts with Raptor to Form a Nutrient-Sensitive Complex that Signals to the Cell Growth Machinery
Kim, D., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument‐Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 3,051
Self-citation
Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the Cytoskeleton
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Self-citation
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Self-citation
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive
Jacinto, E., Loewith, R., Schmidt, A., Lin, S., Rüegg, M. A., Hall, A., & Hall, M. N. (2004) · Nature Cell Biology · doi:10.1038/ncb1183 · Cited by 2,097
Two TOR Complexes, Only One of which Is Rapamycin Sensitive, Have Distinct Roles in Cell Growth Control
Loewith, R., Jacinto, E., Wullschleger, S., Lorberg, A., Crespo, J. L., Bonenfant, D., Oppliger, W., Jenoe, P., & Hall, M. N. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00636-6 · Cited by 1,886

Show all 94 references

Sorted by citations

Items 101–200 of 1,000

mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment
Mafi, S., Mansoori, B., Taeb, S., Sadeghi, H., Abbasi, R., Cho, W. C. S., & Rostamzadeh, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.774103 · Cited by 238
Discovery of 9-(6-Aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a Potent, Selective, and Orally Available Mammalian Target of Rapamycin (mTOR) Inhibitor for Treatment of Cancer
Liu, Q., Wang, J., Kang, S. A., Thoreen, C. C., Hur, W., Ahmed, T., Sabatini, D. M., & Gray, N. S. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101520v · Cited by 226
Self-citation
Discrete mechanisms of mTOR and cell cycle regulation by AMPK agonists independent of AMPK
Liu, X., Chhipa, R. R., Pooya, S., Wortman, M. D., Yachyshin, S., Chow, L. M. L., Kumar, A., Zhou, X., Sun, Y. H., Quinn, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311121111 · Cited by 232
Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors
Doghman, M., Wakil, A. E., Cardinaud, B., Thomas, E., Wang, J., Zhao, W., Peralta-Del Valle, M. H. C., Figueiredo, B. C., Zambetti, G. P., & Lalli, E. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3970 · Cited by 221
Crosstalk Between the PI3K/mTOR and MEK/ERK Pathways Involved in the Maintenance of Self-Renewal and Tumorigenicity of Glioblastoma Stem-Like Cells
Sunayama, J., Matsuda, K.-I., Sato, A., Tachibana, K., Suzuki, K., Narita, Y., Shibui, S., Sakurada, K., Kayama, T., Tomiyama, A., et al. (2010) · Stem Cells · doi:10.1002/stem.521 · Cited by 218
Targeting the PI3K signaling pathway in cancer therapy
Bartholomeusz, C., & Gonzalez-Angulo, A. M. (2012) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.644788 · Cited by 218
Tel2 Regulates the Stability of PI3K-Related Protein Kinases
Takai, H., Wang, R. C., Takai, K., Yang, H., & de Lange, T. (2007) · Cell · doi:10.1016/j.cell.2007.10.052 · Cited by 226
Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer
Sato, T., Nakashima, A., Guo, L., Coffman, K., & Tamanoi, F. (2010) · Oncogene · doi:10.1038/onc.2010.28 · Cited by 223
Recent advances and limitations of mTOR inhibitors in the treatment of cancer
Ali, E. S., Mitra, K., Akter, S., Ramproshad, S., Mondal, B., Khan, I. N., Islam, M. T., Sharifi‐Rad, J., Călina, D. C., & Cho, W. C. S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02706-8 · Cited by 228
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
Turner, N. C., Neven, P., Loibl, S., & Andre, F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32419-9 · Cited by 205
Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
Zhou, Q., Lui, V. W. Y., & Yeo, W. (2011) · Future Oncology · doi:10.2217/fon.11.95 · Cited by 217
Dissecting fibrosis: therapeutic insights from the small-molecule toolbox
Nanthakumar, C. B., Hatley, R. J. D., Lemma, S., Gauldie, J., Marshall, R. P., & Macdonald, S. J. F. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4592 · Cited by 213
Current and upcoming therapies to modulate skin scarring and fibrosis
Coentro, J. Q., Pugliese, E., Hanley, G., Raghunath, M., & Zeugolis, D. I. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.08.009 · Cited by 207
An Overview of Lipid Metabolism and Nonalcoholic Fatty Liver Disease
Pei, K., Gui, T., Kan, D., Feng, H., Jin, Y., Yang, Y., Zhang, Q., Du, Z., Gai, Z., Wu, J., et al. (2020) · BioMed Research International · doi:10.1155/2020/4020249 · Cited by 209
Accelerated wound healing by mTOR activation in genetically defined mouse models
Squarize, C. H., Castilho, R. M., Bugge, T. H., & Gutkind, J. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010643 · Cited by 203
TORC1 Is Essential for NF1-Associated Malignancies
Johannessen, C. M., Johnson, B. W., Williams, S. M. G., Chan, A. W., Reczek, E. E., Lynch, R. C., Rioth, M. J., McClatchey, A. I., Ryeom, S. W., & Cichowski, K. M. (2008) · Current Biology · doi:10.1016/j.cub.2007.11.066 · Cited by 202
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation
Green, A. S., Chapuis, N., Trovati Maciel, T., Willems, L., Lambert, M., Arnoult, C., Boyer, O., Bardet, V., Park, S., Foretz, M., et al. (2010) · Blood · doi:10.1182/blood-2010-02-269837 · Cited by 199
Specific Activation of mTORC1 by Rheb G-protein in Vitro Involves Enhanced Recruitment of Its Substrate Protein
Sato, T., Nakashima, A., Guo, L., & Tamanoi, F. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809207200 · Cited by 196
Autophagy in health and disease. 1. Regulation and significance of autophagy: an overview
Mehrpour, M., Esclatine, A., Beau, I., & Codogno, P. (2010) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00507.2009 · Cited by 211
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma
Zhu, A. X., Abrams, T. A., Miksad, R. A., Blaszkowsky, L. S., Meyerhardt, J. A., Zheng, H., Muzikansky, A., Clark, J. W., Kwak, E. L., Schrag, D., et al. (2011) · Cancer · doi:10.1002/cncr.26165 · Cited by 197
Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer
Araki, K., & Miyoshi, Y. (2017) · Breast Cancer · doi:10.1007/s12282-017-0812-x · Cited by 201
Angiogenesis in prostate cancer: onset, progression and imaging
Russo, G., Mischi, M., Scheepens, W. A., de la Rosette, J. J. M. C. H., & Wijkstra, H. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2012.11444.x · Cited by 203
Regulation of cyclin D1 expression by mTORC1 signaling requires eukaryotic initiation factor 4E-binding protein 1
Averous, J., Fonseca, B. D., & Proud, C. G. (2008) · Oncogene · doi:10.1038/sj.onc.1210715 · Cited by 194
PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
Leiphrakpam, P., & Are, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063178 · Cited by 193
A Dual Phosphoinositide-3-Kinase α/mTOR Inhibitor Cooperates with Blockade of Epidermal Growth Factor Receptor in PTEN -Mutant Glioma
Fan, Q.-W., Cheng, C. K., Nicolaides, T. P., Hackett, C. S., Knight, Z. A., Shokat, K. M., & Weiss, W. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2154 · Cited by 192
Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia
Tamburini, J., Green, A. S., Bardet, V., Chapuis, N., Park, S., Willems, L., Uzunov, M., Ifrah, N., Dreyfus, F., Lacombe, C., et al. (2009) · Blood · doi:10.1182/blood-2008-10-184515 · Cited by 203
mTOR signaling in glioblastoma: lessons learned from bench to bedside
Akhavan, D., Cloughesy, T. F., & Mischel, P. S. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq052 · Cited by 195
Regulation of mTOR by Phosphatidic Acid?
Foster, D. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3016 · Cited by 196
Signaling specificity in the Akt pathway in biology and disease
Toker, A., & Marmiroli, S. (2014) · Advances in Biological Regulation · doi:10.1016/j.jbior.2014.04.001 · Cited by 188
Tumor Cell Autophagy as an Adaptive Response Mediating Resistance to Treatments Such as Antiangiogenic Therapy
Hu, Y., Jahangiri, A., DeLay, M., & Aghi, M. K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1076 · Cited by 190
Cancer gene discovery in hepatocellular carcinoma
Zender, L., Villanueva, A., Tovar, V., Sia, D., Chiang, D. Y., & Llovet, J. M. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.12.034 · Cited by 187
Rapamycin unbalances the polarization of human macrophages to M 1
Mercalli, A., Calavita, I., Dugnani, E., Citro, A., Cantarelli, E., Nano, R., Melzi, R., Maffi, P., Secchi, A., Sordi, V., et al. (2013) · Immunology · doi:10.1111/imm.12126 · Cited by 192
Silibinin inhibits hypoxia-inducible factor-1α and mTOR/p70S6K/4E-BP1 signalling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy
García-Maceira, P., & Mateo, J. (2008) · Oncogene · doi:10.1038/onc.2008.398 · Cited by 185
Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance
Chang, L., Graham, P., Ni, J., Hao, J., Bucci, J. A., Cozzi, P. J., & Li, Y. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.07.005 · Cited by 188
Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin
Rini, B. I. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4719 · Cited by 183
Liver Damage, Inflammation, and Enhanced Tumorigenesis after Persistent mTORC1 Inhibition
Umemura, A., Park, E. J., Taniguchi, K., Lee, J. H., Shalapour, S., Valasek, M. A., Aghajan, M., Nakagawa, H., Seki, E., Hall, M. N., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.05.001 · Cited by 184
Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex
Goto, J., Talos, D. M., Klein, P., Qin, W., Chekaluk, Y. I., Anderl, S., Malinowska, I. A., Nardo, A. D., Bronson, R. T., Chan, J. A.-W., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106454108 · Cited by 176
p27: A Barometer of Signaling Deregulation and Potential Predictor of Response to Targeted Therapies
Wander, S. A., Zhao, D., & Slingerland, J. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0752 · Cited by 176
The metabolic demands of cancer cells are coupled to their size and protein synthesis rates
Dolfi, S. C., Chan, L. L., Qiu, J., Tedeschi, P. M., Bertino, J. R., Hirshfield, K. M., Oltvai, Z. N., & Vázquez, A. (2013) · Cancer & Metabolism · doi:10.1186/2049-3002-1-20 · Cited by 183
mTORC1 and Nutrient Homeostasis: The Central Role of the Lysosome
Rabanal‐Ruiz, Y., & Korolchuk, V. I. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030818 · Cited by 178
Targeting ageing with rapamycin and its derivatives in humans: a systematic review
Lee, D., Kuerec, A. H., & Maier, A. B. (2024) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(23)00258-1 · Cited by 184
Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1 in mice
Gong, Q., Hu, Z., Zhang, F., Cui, A., Chen, X., Jiang, H., Gao, J., Chen, X., Han, Y., Liang, Q., et al. (2016) · Hepatology · doi:10.1002/hep.28523 · Cited by 171
Targeting the AKT protein kinase for cancer chemoprevention
Crowell, J. A., Steele, V. E., & Fay, J. R. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0120 · Cited by 173
PI3K/Akt/mTOR signaling pathway in cancer stem cells
Fath, M. K., Ebrahimi, M., Nourbakhsh, E., Hazara, A. Z., Mirzaei, A., Shafieyari, S., Salehi, A., Hoseinzadeh, M., Payandeh, Z., & Barati, G. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154010 · Cited by 173
Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability
Pajvani, U. B., Qiang, L., Kangsamaksin, T., Kitajewski, J., Ginsberg, H. N., & Accili, D. (2013) · Nature Medicine · doi:10.1038/nm.3259 · Cited by 172
mTOR Is Activated in the Majority of Malignant Melanomas
Karbowniczek, M., Spittle, C. S., Morrison, T., Wu, H., & Henske, E. P. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701074 · Cited by 168
Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound –Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma
Cirstea, D. D., Hideshima, T., Rodig, S. J., Santo, L., Pozzi, S., Vallet, S., Ikeda, H., Perrone, G., Görgün, G., Patel, K. J., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0763 · Cited by 168
Regulation of Akt signaling activation by ubiquitination
Yang, W.-L., Wu, C.-Y., Wu, J., & Lin, H.-K. (2010) · Cell Cycle · doi:10.4161/cc.9.3.10508 · Cited by 164
Cellular transformation by human papillomaviruses: Lessons learned by comparing high- and low-risk viruses
Klingelhutz, A. J., & Roman, A. (2012) · Virology · doi:10.1016/j.virol.2011.12.018 · Cited by 177
mTOR signaling in tumorigenesis
Xu, K. L., Liu, P., & Wei, W. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.10.007 · Cited by 167
Chronotherapy and the molecular clock: Clinical implications in oncology☆
Innominato, P. F., Lévi, F., & Bjarnason, G. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.06.002 · Cited by 168
Targeting pyruvate dehydrogenase kinase signaling in the development of effective cancer therapy
Anwar, S., Shamsi, A., Mohammad, T., Islam, A., & Hassan, M. I. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188568 · Cited by 168
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
Gupta, M., Ansell, S. M., Novak, A. J., Kumar, S. K., Kaufmann, S. H., & Witzig, T. E. (2009) · Blood · doi:10.1182/blood-2009-05-220889 · Cited by 163
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors
Soria, J., Shepherd, F. A., Douillard, J., Wolf, J., Giaccone, G., Crinò, L., Cappuzzo, F., Sharma, S., Gross, S. H., Dimitrijević, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp060 · Cited by 163
Oncogenic regulation of tumor metabolic reprogramming
Tarrado‐Castellarnau, M., de Atauri, P., & Cascante, M. (2016) · Oncotarget · doi:10.18632/oncotarget.10911 · Cited by 165
P-Rex1 Links Mammalian Target of Rapamycin Signaling to Rac Activation and Cell Migration
Hernández-Negrete, I., Carretero-Ortega, J., Rosenfeldt, H. M., Hernández-García, R., Calderón-Salinas, J. V., Reyes‐Cruz, G., Gutkind, J. S., & Vázquez‐Prado, J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703771200 · Cited by 161
Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations
Wykosky, J., Fenton, T. R., Furnari, F. B., & Cavenee, W. K. (2011) · 癌症：英文版 · doi:10.5732/cjc.010.10542 · Cited by 158
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia
Willems, L., Chapuis, N., Puissant, A., Maciel, T. T., Green, A. S., Jacque, N., Vignon, C., Park, S., Guichard, S. M., Hérault, O., et al. (2011) · Leukemia · doi:10.1038/leu.2011.339 · Cited by 172
The evolution of the TOR pathway and its role in cancer
Beauchamp, E. M., & Platanias, L. C. (2012) · Oncogene · doi:10.1038/onc.2012.567 · Cited by 158
Pharmacogenomics in epilepsy
Balestrini, S., & Sisodiya, S. M. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.01.014 · Cited by 158
Hyperplexing: a method for higher-order multiplexed quantitative proteomics provides a map of the dynamic response to rapamycin in yeast
Dephoure, N., & Gygi, S. P. (2012) · Science Signaling · doi:10.1126/scisignal.2002548 · Cited by 153
The Rheb–mTOR Pathway Is Upregulated in Reactive Astrocytes of the Injured Spinal Cord
Codeluppi, S., Svensson, C. I., Hefferan, M. P., Valencia, F., Silldorff, M. D., Oshiro, M., Maršala, M., & Pasquale, E. B. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4103-08.2009 · Cited by 159
Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia
Chapuis, N., Tamburini, J., Green, A. S., Vignon, C., Bardet, V., Neyret, A., Pannetier, M., Willems, L., Park, S., Macone, A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1102 · Cited by 163
Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway
Ching, C. B., & Hansel, D. E. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.133 · Cited by 155
Targeting AMPK: A new therapeutic opportunity in breast cancer
Hadad, S. M., Fleming, S., & Thompson, A. M. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.01.007 · Cited by 158
Proline-rich Akt substrate of 40 kDa (PRAS40): A novel downstream target of PI3k/Akt signaling pathway
Wang, H., Zhang, Q., Wen, Q. J., Zheng, Y., Lazarovici, P., Jiang, H., Lin, J., & Zheng, W. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.08.010 · Cited by 156
Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy
Fu, L., Kim, Y.-A., Wang, X., Wu, X., Yue, P., Lonial, S., Khuri, F. R., & Sun, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2190 · Cited by 153
Topical Rapamycin
Haemel, A. K., O’Brian, A. L., & Teng, J. M. C. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2010.125 · Cited by 149
PTEN Deficiency Contributes to the Development and Progression of Head and Neck Cancer
SQUARIZE, C. H., CASTILHO, R. M., Abrahão, A. C., Molinolo, A., Lingen, M. W., & Gutkind, J. S. (2013) · Neoplasia · doi:10.1593/neo.121024 · Cited by 152
An anti-aging drug today: from senescence-promoting genes to anti-aging pill
Blagosklonny, M. V. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.01.004 · Cited by 150
Cachexia in chronic obstructive pulmonary disease: new insights and therapeutic perspective
Sanders, K. J. C., Kneppers, A. E. M., van de Bool, C., LANGEN, R. C. J., & Schols, A. M. W. J. (2015) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.12062 · Cited by 153
mTOR kinase inhibitors as potential cancer therapeutic drugs
Sun, S. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.06.017 · Cited by 152
Nesfatin-1 Action in the Brain Increases Insulin Sensitivity Through Akt/AMPK/TORC2 Pathway in Diet-Induced Insulin Resistance
Yang, M., Zhang, Z., Wang, C., Li, K., Li, S., Boden, G. H., Li, L., & Yang, G. (2012) · Diabetes · doi:10.2337/db11-1755 · Cited by 149
MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme
Suh, S.-S., Yoo, J. Y., Nuovo, G. J., Jeon, Y.-J., Kim, S., Lee, T. J., Kim, T., Bakàcs, A., Alder, H., Kaur, B., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1202465109 · Cited by 144
FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
Gan, B., Lim, C., Chu, G., Hua, S., Ding, Z., Collins, M. P., HU, J. L., Jiang, S., Fletcher-Sananikone, E., Zhuang, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.019 · Cited by 149
mTORC1 Promotes Denervation-Induced Muscle Atrophy Through a Mechanism Involving the Activation of FoxO and E3 Ubiquitin Ligases
Tang, H., Inoki, K., Lee, M. C., Wright, E., Khuong, A., Khuong, A., Sugiarto, S., Garner, M. S., Paik, J., DePinho, R. A., et al. (2014) · Science Signaling · doi:10.1126/scisignal.2004809 · Cited by 145
Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Blockade Is an Effective Radiosensitizing Strategy for the Treatment of Non–Small Cell Lung Cancer Harboring K-RAS Mutations
Konstantinidou, G., Bey, E. A., Rabellino, A., Schuster, K., Maira, M. S., Gazdar, A. F., Amici, A., Boothman, D. A., & Scaglioni, P. P. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0823 · Cited by 142
Mammalian phospholipase D physiological and pathological roles
Peng, X., & Frohman, M. A. (2011) · Acta Physiologica · doi:10.1111/j.1748-1716.2011.02298.x · Cited by 147
Mammalian Target of Rapamycin Regulates Nox4-Mediated Podocyte Depletion in Diabetic Renal Injury
Eid, A. A., Ford, B. M., Bhandari, B. K., Cavaglieri, R. D. C., Block, K. L., Barnes, J. L., Gorin, Y. C., Choudhury, G. G., & Abboud, H. E. (2013) · Diabetes · doi:10.2337/db12-1504 · Cited by 141
Mammalian gonocyte and spermatogonia differentiation: recent advances and remaining challenges
Manku, G., & Culty, M. (2015) · Reproduction · doi:10.1530/rep-14-0431 · Cited by 140
Posttranslational regulation of Akt in human cancer
Chan, C., Jo, U., Kohrman, A. Q., Rezaeian, A. H., Chou, P.-C., Logothetis, C. J., & Lin, H. (2014) · Cell & Bioscience · doi:10.1186/2045-3701-4-59 · Cited by 143
Targeting mammalian target of rapamycin by rapamycin prevents tumor progression in an oral-specific chemical carcinogenesis model
Czerninski, R., Amornphimoltham, P., Patel, V., Molinolo, A. A., & Gutkind, J. S. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0147 · Cited by 140
Autophagy modulation for cancer therapy
Yang, Z. J., Chee, C. E., Huang, S., & Sinicrope, F. A. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.2.14663 · Cited by 140
Inactivation of Rheb by PRAK-mediated phosphorylation is essential for energy-depletion-induced suppression of mTORC1
Zheng, M., Wang, Y., Wu, X., Wu, S., Lu, B.-J., Dong, M., Zhang, H., Sun, P., Lin, S., Guan, K., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2168 · Cited by 142
Gα i1 and Gα i3 Are Required for Epidermal Growth Factor–Mediated Activation of the Akt-mTORC1 Pathway
Cao, C., Huang, X., Han, Y., Wan, Y., Birnbaumer, L., Feng, G. S., Marshall, J. J., Jiang, M., & Chu, W. (2009) · Science Signaling · doi:10.1126/scisignal.2000118 · Cited by 137
Role of TOR signaling in aging and related biological processes in Drosophila melanogaster
Katewa, S. D., & Kapahi, P. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2010.11.036 · Cited by 139
Mutant p53-R273H mediates cancer cell survival and anoikis resistance through AKT-dependent suppression of BCL2-modifying factor (BMF)
Tan, B. S., Tiong, K. H., Choo, H. L., Chung, F. F., Hii, L., Tan, S. H., Yap, I. K., Pani, S., Khor, N. T., Wong, S. F., et al. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.191 · Cited by 138
RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma
Huynh, H. T., Chow, P. K. H., Soo, K. C., Toh, H. C., Choo, S. P., Foo, K. F., Poon, D. Y. H., Ngo, V. C., & Tran, E. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00364.x · Cited by 134
Cadmium induces autophagy through ROS-dependent activation of the LKB1–AMPK signaling in skin epidermal cells
Son, Y., Wang, X., Hitron, J. A., Zhang, Z., Cheng, S., Budhraja, A., Ding, S., Lee, J., & Shi, X. (2011) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2011.06.024 · Cited by 136
Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding
Sami, A., & Karsy, M. J. (2013) · Tumor Biology · doi:10.1007/s13277-013-0800-5 · Cited by 137
Targeting the Tumor Microenvironment: Focus on Angiogenesis
Fan, F., Schimming, A., Jaeger, D., & Podar, K. (2011) · Journal of Oncology · doi:10.1155/2012/281261 · Cited by 139
KLHL22 activates amino-acid-dependent mTORC1 signalling to promote tumorigenesis and ageing
Chen, J., Ou, Y., Yang, Y., Li, W., Xu, Y., Xie, Y., & Liu, Y. (2018) · Nature · doi:10.1038/s41586-018-0128-9 · Cited by 131
mTOR inhibitors in the treatment of cancer
Fasolo, A., & Sessa, C. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.11.1717 · Cited by 132
Mutation of the PDK1 PH Domain Inhibits Protein Kinase B/Akt, Leading to Small Size and Insulin Resistance
Bayascas, J. R., Wullschleger, S., Sakamoto, K., García‐Martínez, J. M., Clacher, C., Komander, D., van Aalten, D. M. F., Boini, K. M., Lang, F. J. W., Lipina, C., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.02032-07 · Cited by 136
Negative regulation of autophagy
Liang, C. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.115 · Cited by 132
Phosphoinositide 3-kinases as a common platform for multi-hormone signaling
Hirsch, E., Costa, C., & Ciraolo, E. (2007) · Journal of Endocrinology · doi:10.1677/joe-07-0097 · Cited by 132
Multi-mechanisms are involved in reactive oxygen species regulation of mTORC1 signaling
Li, M., Zhao, L., Liu, J., Liu, A., Jia, C., Ma, D., Jiang, Y., & Bai, X. (2010) · Cellular Signalling · doi:10.1016/j.cellsig.2010.05.015 · Cited by 132
Tumor Cells Switch to Mitochondrial Oxidative Phosphorylation under Radiation via mTOR-Mediated Hexokinase II Inhibition - A Warburg-Reversing Effect
Lu, C., Qin, L., Liu, H.-C., Candas, D., Fan, M., & Li, J. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121046 · Cited by 138
Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway
Gu, Z., Tan, W., Ji, J., Feng, G., Meng, Y., Da, Z., Guo, G., Xia, Y., Zhu, X., Shi, G., et al. (2016) · Aging · doi:10.18632/aging.100925 · Cited by 129
Global Downstream Pathway Analysis Reveals a Dependence of Oncogenic NF-E2–Related Factor 2 Mutation on the mTOR Growth Signaling Pathway
Shibata, T., Saito, S., Kokubu, A., Suzuki, T., Yamamoto, M. P., & Hirohashi, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0384 · Cited by 133

Authors: Sabatini, D. M.
Affiliations: Whitehead Institute for Biomedical Research (US)
Corresponding author: Sabatini, David M.
ORCID: Sabatini, David M.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2006-08-17
Volume: 6
Issue: 9
Pages: 729-734
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc1974
OpenAlex: W2060157525
Cited by: 1,322
References: 94
Citations by year: 2026: 10 · 2025: 21 · 2024: 31 · 2023: 46 · 2022: 38 · 2021: 33 · 2020: 51 · 2019: 52 · 2018: 60 · 2017: 62 · 2016: 79 · 2015: 87 · 2014: 80 · 2013: 102 · 2012: 98
FWCI: 6.72
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Funders: Pew Charitable Trusts
Rita Allen Foundation
Allen Foundation
National Trust for Historic Preservation
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: mTOR, mTOR inhibitors, mTORC1, mTORC2, cancer therapy, mechanism of action, rapamycin, kinase signaling, targeted cancer drugs
MeSH terms: Antineoplastic Agents, Humans, Neoplasms, Protein Kinases, Signal Transduction, Protein Kinase Inhibitors, TOR Serine-Threonine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

mTOR and cancer: insights into a complex relationship

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks